Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Interventions: ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection; Procedure · Drug · Radiation
Lead sponsor: Institute of Cancer Research, United Kingdom; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Childhood Obesity
Interventions: Grow Together peer group; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Menorrhagia, Heavy Menstrual Bleeding, Heavy Uterine Bleeding
Interventions: Minitouch System; Device
Lead sponsor: MicroCube, LLC; Industry
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Newburgh, Indiana • Mason, Ohio • Austin, Texas

Conditions: Spinal Cord Injuries
Interventions: Neurophysiological and anatomical testing, Transcutaneous Spinal Stimulation; Diagnostic Test · Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Dentatorubral-Pallidoluysian Atrophy
Interventions: nL-ATN1-002; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 17 Years to 17 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions: lisocabtagene maraleucel; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 59
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: Healthy
Interventions: IMA-638; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 20 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Glendale, California

Conditions: Partial Edentulism, Tooth Disease
Interventions: Not listed
Lead sponsor: ZimVie; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Choroideremia
Interventions: BIIB111; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Boston, Massachusetts • Cincinnati, Ohio + 1 more

Conditions: Schizophrenia
Interventions: TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Congenital Heart Disease, Cardiac Output, Hemodynamic Monitoring, Pediatric Heart Disease
Interventions: UltraTrac; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 0 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Irritable Bowel Syndrome
Interventions: Elemental Diet; Dietary Supplement
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Insomnia
Interventions: Internet-based Self-help Insomnia Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers, Abdominal Cancer
Interventions: Next Generation Delivery System (NGDS); Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Human Influenza
Interventions: Standard dose influenza vaccination, High dose influenza vaccination; Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions: Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control); Biological · Other
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Sioux Falls, South Dakota

Conditions: Healthy
Interventions: Alendronate Sodium Tablets, 10 mg, Fosamax Tablets, 10 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Solid Tumors
Interventions: dovitinib, fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Las Vegas, Nevada • The Bronx, New York

Conditions: Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions: RNDO-564, Pembrolizumab; Drug
Lead sponsor: Rondo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more

Conditions: Plaque Psoriasis
Interventions: PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Lung Cancer
Interventions: Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 70 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 18
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more

Conditions: Healthy
Interventions: Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes, Interleukins, Cytokines
Interventions: laparoscopic gastric bypass plus omentectomy; Procedure
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Healthy Growth Abbreviated Pilot Study

Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness

Spinal Neurorehabilitation for Veterans With SCI

Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Study Evaluating IMA-638 in Healthy Japanese

A Study of Osseotite Certain Prevail Implants Used to Support Short Fixed Bridges With Immediate Occlusal Loading.

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

UltraTrac for Cardiac Output Monitoring in Congenital Heart Disease

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Elemental Diet and Gut Microbiome

Implementing and Evaluating Computer-Based Interventions for Mental Health: Testing an Implementation Strategy for VA Outpatient Care

A Study Evaluating a New Radiation Treatment Workflow (NGDS)

Tfh Dysfunction in HIV and Aging

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices